MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says interim results from the CimetrA study show no significant Covid-19 related complications, compared to 63% of placebo group who reported adverse events related to Covid-19 symptoms. The study had 16 participants with Covid-19. No patients from either drug study group showed any Covid-19 related adverse events, it noted. It also notes improvements in multiple parameters measuring the patient's clinical condition, such as respiratory rate and oxygen saturation, when compared to placebo.
"Whilst the sample size on which the interim analysis has been performed is small and cannot be used for Inferential statistical analysis, the results thus far are very encouraging and in line with the company's expectations," MGC says.
Current stock price: 0.93 pence
12-month change: down 71%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.